Introduction {#sec1}
============

During hematopoiesis, hematopoietic stem cells (HSCs) activate specific sets of genes and silence others. Transcription factors fulfill an obvious role in this process. At the same time, chromatin modifiers regulate the accessibility of transcription factors to *cis* elements by establishing regions of chromatin that are either permissive or repressive to transcription. These epigenetic transcriptional regulations are crucial for the maintenance of multipotency in stem cells ([@bib13; @bib12]). Polycomb group (PcG) proteins, which establish a reversible silencing state through repressive histone modifications, maintain multipotency of HSCs by keeping hematopoietic developmental regulator genes poised for activation via bivalent histone domains ([@bib9]). However, the mechanisms by which nonhematopoietic genes, which should never be activated in the hematopoietic cell lineage, are transcriptionally repressed remain to be elucidated.

TIF1β (also called KAP1 or TRIM28) is a transcriptional corepressor that associates with hundreds of Kruppel-associated box domain-zinc finger proteins (KRAB-ZFPs) that bind DNA in a sequence-specific fashion. TIF1β acts as a scaffold for a multimolecular complex that silences transcription through the formation of heterochromatin by recruiting the histone methyltransferase SETDB1, heterochromatin protein 1 (HP1), or the NuRD-histone deacetylase complex ([@bib8; @bib14; @bib15]). The KRAB/KAP1 system plays a critical role in the control of endogenous retroviruses during development ([@bib10; @bib11]) but also regulates multiple aspects of mammalian physiology. In hematopoiesis, it functions in erythropoiesis and in the prevention of autoinflammatory T cell development ([@bib5; @bib1]).

In this study, we demonstrate an essential role for the TIF1β/HP1 system in the maintenance of HSCs and implicate this system in the establishment of transcriptional signature of HSCs by keeping nonhematopoietic genes transcriptionally silent.

Results and Discussion {#sec2}
======================

Deletion of *Tif1b* Severely Compromises HSC Function in the Fetal Liver {#sec2.1}
------------------------------------------------------------------------

*Tif1b*-deficient mice show early developmental defects and die by embryonic day 7.5 (E7.5) ([@bib2]). To delineate function of TIF1β in HSCs, we conditionally deleted *Tif1b* by crossing *Tif1b*^fl/fl^ mice with *Tie2-Cre* mice, which specifically express *Cre* in hematopoietic and endothelial cells (*Tie2-Cre;Tif1b*^fl/fl^). We confirmed efficient deletion of *Tif1b* in fetal liver lineage-marker (Lin)^−^c-KIT^+^ hematopoietic progenitor cells from *Tie2-Cre;Tif1b* mice by western blot and immunocytochemical analyses in Lin^−^c-KIT^+^SCA-1^+^ (LSK) hematopoietic stem and progenitor cells (HSPCs) ([Figures S1](#app3){ref-type="sec"}A and S1B available online). *Tie2-Cre;Tif1b*^fl/fl^ embryos were recovered at nearly the expected Mendelian ratio at E13.5, but about 28% (58 out of 207 *Tie2-Cre;Tif1b*^fl/fl^ embryos) were already dead and no mutant embryos were born alive (data not shown). *Tie2-Cre;Tif1b*^fl/fl^ embryos were pale and their fetal livers were significantly smaller than those of the littermate controls ([Figures 1](#fig1){ref-type="fig"}A and 1B). Flow cytometric analyses demonstrated a significant reduction in TER119^+^ erythroblasts in *Tie2-Cre;Tif1b*^fl/fl^ fetal livers ([Figure 1](#fig1){ref-type="fig"}B). Detailed analysis revealed a block in differentiation of *Tif1b*^Δ/Δ^ erythroblasts from CD71^+^TER119^−^ early erythroblasts to CD71^+^TER119^+^ erythroblasts ([Figure S1](#app3){ref-type="sec"}C), resulting in a drastic reduction in the numbers of *Tif1b*^Δ/Δ^ CD71^+^TER119^+^ and CD71^−^TER119^+^ mature erythroblasts ([Figure 1](#fig1){ref-type="fig"}C). Indeed, *Tif1b*^Δ/Δ^ erythroblasts were mostly proerythroblasts, while the control erythroblasts were at various differentiation stages from proerythroblasts to mature erythroblasts ([Figure 1](#fig1){ref-type="fig"}D). These data are consistent with the recent reports on the impact of deletion of *Tif1b* on erythropoiesis ([@bib1]), suggesting that severe anemia due to impaired erythroid differentiation could account for embryonic lethality of *Tie2-Cre;Tif1b*^fl/fl^ embryos.

Of note, CD150^+^LSK HSCs and LSK HSPCs were also significantly reduced in *Tie2-Cre;Tif1b*^fl/fl^ fetal livers at E13.5 compared to the controls ([Figures 1](#fig1){ref-type="fig"}E and [S1](#app3){ref-type="sec"}D). *Tif1b*^f/Δ^ LSK cells proliferated poorly in liquid culture compared to the control cells ([Figure 1](#fig1){ref-type="fig"}F). In colony-forming assays, *Tif1b*^Δ/Δ^ LSK cells gave rise to significantly fewer colonies than control cells and failed to form colonies larger than 2 mm in diameter. Most of the colonies generated from *Tif1b*^Δ/Δ^ LSK cells consisted of only neutrophils and macrophages with very few megakaryocytes but completely lacked erythroblasts ([Figure 1](#fig1){ref-type="fig"}G). We next performed competitive reconstitution assays. Not surprisingly, *Tif1b*^Δ/Δ^ cells did not contribute to hematopoiesis in the recipient mice in either the peripheral blood (PB) or the bone marrow (BM) ([Figure 1](#fig1){ref-type="fig"}H). Further examination revealed that *Tif1b*^+/Δ^ cells also performed poorly in competitive reconstitution assays, suggesting a haploinsufficient effect with *Tif1b* heterozygotes (data not shown). Moreover, *Tif1b*^Δ/Δ^ cells failed to extend the survival of lethally irradiated recipient mice ([Figure S1](#app3){ref-type="sec"}E). These results indicate that loss of TIF1β severely impairs the capacity of HSCs to repopulate hematopoiesis in vivo.

Deletion of *Tif1b* Causes BM Failure Accompanied by Depletion of HSCs {#sec2.2}
----------------------------------------------------------------------

To evaluate the role of TIF1β in adult BM hematopoiesis, we next analyzed *Cre-ERT;Tif1b*^fl/fl^ mice. To exclude any influences of deletion of *Tif1b* on the BM microenvironment, we first transplanted BM cells from *Cre-ERT* control and *Cre-ERT;Tif1b*^fl/fl^ mice without competitor cells into lethally irradiated wild-type recipient mice. After confirming engraftment, we deleted *Tif1b* by inducing nuclear translocation of Cre with intraperitoneal injection of tamoxifen at 8 weeks after transplantation. Deletion of *Tif1b* was very efficient, with deletion efficiency in BM Lin^−^c-KIT^+^ progenitor cells at 92.6% by genomic quantitative PCR (data not shown). As indicated by mild reduction in BM cellularity and mild cytopenia in *Cre-ERT* control mice, tamoxifen had some toxic effects on hematopoiesis at the early time points postinjection ([Figures 2](#fig2){ref-type="fig"}B and [S2](#app3){ref-type="sec"}A). Deletion of *Tif1b*, however, induced progressive hypoplasia of the BM and the spleen ([Figures 2](#fig2){ref-type="fig"}A and 2B) and caused obvious cytopenia in the PB ([Figure S2](#app3){ref-type="sec"}A). Although residual Ly5.1^+^ host cells gradually overtook *Tif1b*^Δ/Δ^ cells and eventually restored the blood cell counts in the PB ([Figures S2](#app3){ref-type="sec"}A and S2B), about 70% of the transplanted mice died of BM failure within 40 days of tamoxifen injection ([Figure 2](#fig2){ref-type="fig"}C).

Of interest, the number of *Tif1b*^Δ/Δ^ HSCs increased transiently at 2 weeks postdeletion and then dramatically decreased by 4 weeks postdeletion ([Figure 2](#fig2){ref-type="fig"}D), suggesting enhanced cycling of HSCs. Indeed, 66% of the *Tif1b*^Δ/Δ^ HSCs had exited the quiescent G~0~ stage and a significant portion of them were actively cycling compared to the control HSCs ([Figures 2](#fig2){ref-type="fig"}E and [S2](#app3){ref-type="sec"}C). A significant number of *Tif1b*^Δ/Δ^ HSPCs egressed from BM to the periphery as evident from a drastic increase in LSK HSPCs and Lin^−^c-KIT^+^ progenitors in the PB ([Figure 2](#fig2){ref-type="fig"}F), suggesting a BM niche-interaction defect in *Tif1b*^Δ/Δ^ HSPCs. In addition, *Tif1b*^Δ/Δ^ HSCs underwent massive apoptosis ([Figure 2](#fig2){ref-type="fig"}G). Among the myeloid progenitors, the numbers of *Tif1b*^Δ/Δ^ granulocyte-macrophage progenitors (GMPs) and megakaryocyte-erythroid progenitors (MEPs) were also significantly reduced at 4 weeks postdeletion ([Figure S2](#app3){ref-type="sec"}D). Furthermore, *Tif1b*^Δ/Δ^ LSK cells proliferated poorly in culture ([Figure S2](#app3){ref-type="sec"}E). We next examined the long-term reconstitution capacity of *Tif1b*-deficient BM cells. To this end, control and *Cre-ERT;Tif1b*^fl/fl^ BM cells were transplanted along with the same number of BM competitor cells into lethally irradiated wild-type recipients. Upon deletion of *Tif1b* at 8 weeks after transplantation, donor cells were rapidly outcompeted by the competitor cells and quickly depleted from both the PB and the BM ([Figure 2](#fig2){ref-type="fig"}H).

In contrast to its role in erythropoiesis ([@bib1]), the role of TIF1β has never been tested in myeloid cells. We therefore analyzed *lysozyme*-*Cre;Tif1b*^fl/fl^ mice, in which Cre is active only in myeloid cells at the maturation stages beyond GMPs. Surprisingly enough, *lysozyme*-*Cre;Tif1b*^fl/fl^ mice showed no obvious defects in myeloid differentiation. The hematological data, including the PB cell counts and the lineage composition and the number of BM cells, myeloid progenitor cells and HSCs were almost normal ([Figure S3](#app3){ref-type="sec"}). These findings underline the lineage-specific functions of TIF1β in hematopoiesis.

Loss of HSC Signature in the Absence of TIF1β {#sec2.3}
---------------------------------------------

To elucidate the changes in gene expression responsible for impaired HSC function in the absence of TIF1β, we performed microarray analysis using LSK cells at 2 weeks postdeletion of *Tif1b* ([Figure 3](#fig3){ref-type="fig"}A). The analysis revealed that 541 genes were upregulated more than 2-fold and 486 genes were downregulated more than 2-fold compared to control cells reproducibly in two independent experiments. We first performed gene set enrichment analysis (GSEA) to see if there was a fundamental loss of stem-cell-like gene expression in *Tif1b*^Δ/Δ^ HSCs. Using the microarray data taken from various hematopoietic compartments (CD34^−^LSK HSCs, CD34^+^LSK MPPs, Lin^−^c-KIT^+^ committed progenitors, and Lin^+^ differentiated cells), we found that a gene signature unique to CD34^−^LSK HSCs was actually enriched in *Tif1b*^Δ/Δ^LSKs ([Figure 3](#fig3){ref-type="fig"}B). This suggests that a loss of "stemness" is not responsible for the phenotypes observed in *Tif1b*-deficient mice.

We next focused on the genes derepressed in the absence of TIF1β. Among genes derepressed, a significant portion of genes became transcriptionally detectable from undetectable levels ("activated") in *Tif1b*^Δ/Δ^ LSK cells ([Figure 3](#fig3){ref-type="fig"}C). We then compared the expression profiles of the "activated" genes in *Tif1b*^Δ/Δ^ BM LSK cells to various hematopoietic compartments, including CD34^−^LSK HSCs, CD34^+^LSK MPPs, Lin^−^c-KIT^+^ committed progenitors, and Lin^+^ differentiated cells ([Figure 3](#fig3){ref-type="fig"}D). To our surprise, the majority of "activated" gene transcripts were not detected in any of these hematopoietic compartments ([Figure 3](#fig3){ref-type="fig"}E). These results suggest that TIF1β is required for the gene silencing of nonhematopoietic genes in HSPCs.

Among gene sets positively enriched (derepressed) in *Tif1b*^Δ/Δ^ LSK cells, many genes sets were related to signaling pathways mediated by cell surface receptors or adhesion molecules (e.g., integrin signaling pathway, gap junction, and focal adhesion; see [Table S1](#app3){ref-type="sec"}) and upregulation of such genes was confirmed by quantitative RT-PCR ([Figure S4](#app3){ref-type="sec"}A). These results indicate deregulated expression of nonhematopoietic adhesion molecules in *Tif1b*^Δ/Δ^ HSCs, which might result in impaired niche interaction in *Tif1b*^Δ/Δ^ HSCs and enhanced egression of HSCs from the BM to the periphery.

[@bib1] have recently reported that deletion of *Tif1b* results in compromised erythropoiesis due to failure in the induction of mitophagy-related genes. They found that the TIF1β together with KRAB-ZNF represses the transcription of microRNAs (miRNAs) targeting mitophagy transcripts to induce mitophagy during the terminal differentiation of erythroblasts. Profiling of miRNAs in *Tif1b*^Δ/Δ^ LSK cells revealed upregulation of 15 miRNA greater than 2-fold compared to control cells ([Figure 3](#fig3){ref-type="fig"}F). However, none of the mitophagy-related miRNAs described by Barde et al. were upregulated in *Tif1b*^Δ/Δ^ LSK cells. In addition, the expression levels of mitophagy-related genes were not significantly altered in *Tif1b*^Δ/Δ^ LSK cells (data not shown). Together, these findings highlight the cell-type-specific as well as differentiation stage-specific functions of TIF1β in hematopoiesis. Nonetheless, it should be noted that some of the upregulated miRNAs potentially target genes downregulated in *Tif1b*^Δ/Δ^ LSK cells, implying involvement of derepressed miRNAs in altered gene expression in *Tif1b*^Δ/Δ^ LSK cells (data not shown).

TIF1β has been characterized to suppress activation of p53 ([@bib16]). Indeed, p53 target genes, such as proapoptotic genes *Bax*, *Noxa*, and *p21*, were upregulated in fetal *Tif1b*^Δ/Δ^ LSK cells ([Figure S4](#app3){ref-type="sec"}B). In order to evaluate the contribution of p53, we transplanted *Cre-ERT;Tif1b*^fl/fl^ CD34^−^LSK HSCs transduced with the E6 oncoprotein, a potent p53 inhibitor, into lethally irradiated recipients. E6, however, did not have any gross effects on the repopulating capacity of *Tif1b*^Δ/Δ^ HSCs ([Figure S4](#app3){ref-type="sec"}C), suggesting that the activated p53 response is not the causative event in the hematopoietic failure induced by absence of TIF1β.

Reduction in HP1 Proteins in the Absence of TIF1β {#sec2.4}
-------------------------------------------------

TIF1β physically interacts with all of the HP1 proteins (HP1α, HP1β, and HP1γ; [@bib8; @bib3; @bib4]) and recruits them in order to establish deep silencing of their target genes ([@bib8; @bib15]). Notably, levels of all three members of the HP1 family proteins were reduced approximately 2-fold in fetal liver *Tif1b*^Δ/Δ^ Lin^−^c-KIT^+^ progenitor cells ([Figure 4](#fig4){ref-type="fig"}A), though their transcription levels were not significantly changed (data not shown). In accordance with this finding, immunostaining of fetal liver LSK cells revealed a reduction in numbers of chromocenters, a structural component of heterochromatin where HP1α accumulates, in the absence of TIF1β ([Figure 4](#fig4){ref-type="fig"}B). These results support the notion that TIF1β functions as a scaffold that stabilizes HP1 proteins. The level of HP1α protein was significantly reduced also in NIH 3T3 cells depleted of TIF1β. However, inhibition of proteasome activity by MG132 in NIH cells failed to stabilize HP1α upon knockdown of *Tif1b*, leaving the molecular mechanism through which the HP1 proteins are destabilized in the absence of TIF1β still obscure (data not shown). HP1 proteins are recruited to their target loci via physical interaction with TIF1β as well as through direct binding to trimethylated H3K9 to form transcriptionally inactive heterochromatin ([@bib7]). The levels of global histone modifications, including H3K9me1/2/3, did not significantly change in *Tif1b*^Δ/Δ^ Lin^−^c-KIT^+^ progenitor cells ([Figure S4](#app3){ref-type="sec"}D). These findings further suggest that TIF1β regulates HP1 function not only by tethering them to their targets but also by securing their posttranslational stability. In order to test whether the reduction in levels of HP1 proteins is involved in the impaired function of *Tif1b*^Δ/Δ^ HSCs, we knocked down the *Hp1* genes in HSCs using small hairpin RNAs (shRNAs) ([Figure S4](#app3){ref-type="sec"}E). Growth of HSCs was significantly impaired upon depletion of *Hp1a* and *Hp1g*, but not *Hp1b* ([Figure 4](#fig4){ref-type="fig"}C). The proportion of LSK HSPCs in GFP^+^ transduced cells was also significantly decreased upon depletion of *Hp1a* and *Hp1g*, but not *Hp1b*, at day 14 of culture ([Figure 4](#fig4){ref-type="fig"}D). These results suggest that reduced levels of HP1 proteins play a role in determining the phenotypes of *Tif1b*-deficient HSCs. Together, our findings highlight the TIF1β-HP1 system as critical transcriptional machinery that keeps nonhematopoietic genes repressed in HSCs, thereby maintaining the transcriptional signature specific to HSCs.

TIF1β has been reported to repress the expression of endogenous retrotransposons in embryonic stem cells via the histone methyltransferase ESET/SETDB1 and subsequent H3K9 trimethylation ([@bib6; @bib10]). However, we did not observe any significant derepression of endogenous retrotransposons in *Tif1b*^Δ/Δ^ LSK cells (data not shown), indicating that different silencing machineries are operating in embryonic stem cells and somatic stem cells. Of interest, the phenotypes of *Tif1b*^Δ/Δ^ HSCs are similar to those of HSCs deficient for MI-2β, a component of the NuRD histone deacetylase complex, which directly interacts with TIF1β ([@bib14; @bib17]). TIF1β may thus collaborate with the NuRD complex, in addition to HP1 proteins, and stabilize these repressor molecules critical for the transcriptional repression of nonhematopoietic genes in HSCs.

The epigenetic regulation of transcription is crucial for the maintenance of cell-type-specific signatures ([@bib12]). In the point of view of transcriptional regulation, multipotency of stem cells can be defined as an ability of stem cells to express a set of genes required for differentiation and cell-type-specific function upon cell differentiation. The PcG proteins maintain this "transcriptional competence" by transiently silencing genes that will be activated during differentiation of stem cells ([@bib13]). In contrast, our findings in this study indicate that the TIF1β-HP1 system, which collaborates with H3K9me3 and DNA methylation ([@bib11]), is involved in establishing a more stable silencing state of genes that would never be activated in a given cell lineage. However, the precise mechanisms by which the epigenetic switching between the reversible PcG-mediated system and the TIF1β-HP1 system that we propose here remain to be elucidated. Understanding how these different repressive systems work would prove invaluable to our understanding of the epigenetic regulation of stem cells.

Experimental Procedures {#sec3}
=======================

Details regarding experimental procedures are available in [Supplemental Experimental Procedures](#app3){ref-type="sec"}.

Accession Numbers {#app1}
=================

Microarray data have been deposited in the NCBI Gene Expression Omnibus with the accession numbers [GSE48929](ncbi-geo:GSE48929){#intref0010}, [GSE48986](ncbi-geo:GSE48986){#intref0015}, and [GSE52282](ncbi-geo:GSE52282){#intref0020}.
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![*Tie2-Cre;Tif1b*^fl/fl^ Embryos Die at Midgestation\
(A) Appearance of *Tie2-Cre* (*Tif1b*^+/+^) and *Tie2-Cre;Tif1b*^fl/fl^ (*Tif1b*^Δ/Δ^) embryos at E13.5.\
(B) Absolute numbers of whole fetal liver cells, c-KIT^+^ progenitors, and TER119^+^ erythroblasts at E13.5. The data are shown as mean ± SEM (*Tie2-Cre*, n = 16; *Tie2-Cre;Tif1b*^fl/fl^, n = 17).\
(C) Absolute numbers of erythroid cells at different stages defined by CD71 and TER119 expression in fetal livers at E13.5. The data are shown as mean ± SEM (*Tie2-Cre*, n = 16; *Tie2-Cre;Tif1b*^fl/fl^, n = 17).\
(D) Morphology of *Tif1b*^+/+^ and *Tif1b*^Δ/Δ^ fetal liver hematopoietic cells from E13.5 embryos stained with May-Grünwald-Giemsa solution.\
(E) Absolute cell numbers of LSK and CD150^+^LSK cells in the fetal liver at E13.5. The data are shown as mean ± SEM (*Tie2-Cre*, n = 23; *Tie2-Cre;Tif1b*^fl/fl^, n = 21).\
(F) Growth of *Tif1b*^+/+^ and *Tif1b*^Δ/Δ^ LSK cells from E13.5 fetal livers in liquid culture in the presence of 50 ng/ml of SCF and TPO. The data are shown as mean ± SEM for triplicate cultures.\
(G) Colony-forming assays with *Tif1b*^+/+^ and *Tif1b*^Δ/Δ^ fetal liver cells. Left panel shows the absolute number of colonies with the indicated size per 20,000 fetal liver cells. The data are shown as mean ± SEM for triplicate cultures. Right panel shows the proportion of colony types defined by the composition of colony-forming cells (n, neutrophil; m, macrophage; E, erythroblast; M, megakaryocyte).\
(H) Competitive repopulating assays. A total of 2 × 10^5^*Tif1b*^+/+^ and *Tif1b*^Δ/Δ^ fetal liver cells from E13.5 embryos (CD45.2) mixed with the same number of competitor BM cells (CD45.1) were transplanted into CD45.1 recipients. Chimerism of donor-derived CD45.2^+^ cells in the PB is shown in the left panel. Donor chimerism in the BM LSK cells at 12 weeks posttransplantation is shown in the right panel. The data are shown as mean ± SEM (n = 6). ^∗^p \< 0.05; ^∗∗^p \< 0.005; ^∗∗∗^p \< 0.0005.](gr1){#fig1}

![Deletion of *Tif1b* Leads to Rapid BM Failure\
(A) Hematoxylin and eosin staining of BM sections from *Cre-ERT* (*Tif1b*^+/+^) and *Cre-ERT;Tif1b*^fl/fl^ (*Tif1b*^Δ/Δ^) mice at 2 and 4 weeks postdeletion of *Tif1b*. BM cells from 8-week-old *Cre-ERT* and *Cre-ERT;Tif1b*^fl/fl^ mice were transplanted into lethally irradiated recipient mice without competitor cells. At 8 weeks after transplantation, recipient mice were injected with tamoxifen for 5 consecutive days.\
(B) Absolute numbers of total BM and spleen cells at the indicated time points postdeletion of *Tif1b* (2 weeks \[2w\], n = 8; 4 weeks \[4w\], n = 8--10).\
(C) Survival curve of the recipient mice repopulated with BM cells from *Cre-ERT* and *Cre-ERT;Tif1b*^fl/fl^ mice after deletion of *Tif1b* (n = 12).\
(D) Absolute numbers of total *Tif1b*^+/+^ and *Tif1b*^Δ/Δ^ CD34^−^LSK HSCs in the BM at the indicated time points after deletion of *Tif1b* (n = 8).\
(E) Cell-cycle status of *Tif1b*^+/+^ and *Tif1b*^Δ/Δ^ CD34^−^LSK HSCs determined by incorporation of Pyronin Y at 2 weeks after the first injection of tamoxifen. Representative flow cytometric profiles are depicted (upper panel) and the proportion of pyronin Y-negative cells in CD34^−^LSK HSCs is shown as the mean ± SEM (n = 4) (lower panel).\
(F) Detection of *Tif1b*^+/+^ and *Tif1b*^Δ/Δ^ HSPCs in the PB at 2 weeks after the first injection of tamoxifen. Representative flow cytometric profiles of LSK cells from *CreERT* and *CreERT;Tif1b*^fl/fl^ mice are depicted (upper panel) and the proportions of Lin^−^c-Kit^+^ and LSK cells in total mononuclear cells is shown as the mean ± SEM (n = 4) (lower panel).\
(G) Apoptosis in BM CD45.2^+^LSK cells from recipient mice detected with Annexin V and 7-aminoactinomycin D (7-AAD) by flow cytometry at the indicated time points after deletion of *Tif1b*. The data are shown as mean ± SEM (n = 4).\
(H) Competitive reconstitution assays. BM cells from 8-week-old *CreERT* and *CreERT;Tif1b*^fl/fl^ mice were transplanted into lethally irradiated recipient mice with the same number of competitor BM cells (1 × 10^6^ cells). At 8 weeks posttransplantation, recipient mice were injected with tamoxifen for 5 consecutive days. The chimerism of CD45.2^+^ donor-derived cells in the PB of recipient mice is shown as % of chimerism values prior to treatment with tamoxifen (left panel). Donor chimerism in the BM LSK and CD34^−^LSK cells at 12 weeks after injection of tamoxifen is also shown (right panel). The data are shown as mean ± SEM (n = 6). ^∗^p \< 0.05; ^∗∗^p \< 0.005; ^∗∗∗^p \< 0.0005.](gr2){#fig2}

![Derepression of Nonhematopoietic Genes in *Tif1b-*Deficient LSK Cells\
(A) Heatmap of the expression of genes that were upregulated (541 probe sets, upper panel) or downregulated (486 probe sets, lower panel) more than 2-fold in *Tif1b*-deficient BM LSK cells in the microarray analysis.\
(B) GSEA of the gene set specific to CD34^−^LSK HSCs in *Tif1b*^Δ/Δ^ LSK cells. Using the microarray data from CD34^−^LSK HSCs, CD34^+^LSK MPPs, Lin^−^c-KIT^+^ committed progenitors, and Lin^+^ differentiated cells, HSC-specific gene sets were selected and applied to GSEA.\
(C) Upregulated genes in (A) were divided into two groups according to their expression levels in *Tif1b*^Δ/Δ^ LSK cells compared to that in control LSK cells. One group consist of probe sets that were expressed in the control LSK cells and their expression levels were enhanced upon deletion of *Tif1b* ("enhanced" genes). The other group includes probe sets that were not expressed in the control LSK cells but became activated in *Tif1b*-deficient LSK cells ("activated" genes). Bar graph shows proportions of these groups.\
(D) Schematic representation of expression profiles of "Activated" genes in BM *Tif1b*-deficient LSK cells in (A) in various hematopoietic cell fractions, including CD34^−^LSK HSCs, CD34^+^LSK MPPs, Lin^−^c-KIT^+^ committed progenitors, and Lin^+^ differentiated cells. Expressed genes are depicted as a red bar.\
(E) Proportions of probe sets in (D) that were not expressed in any of the hematopoietic cell fractions (Not expressed) and those expressed in at least one of the hematopoietic cell fractions including CD34^−^LSK HSCs, CD34^+^LSK MPPs, Lin^−^c-KIT^+^ committed progenitors and Lin^+^ differentiated cells (Expressed).\
(F) Heatmap of the expression of miRNAs that were upregulated (15 miRs) or downregulated (80 miRs) more than 2-fold in *Tif1b*-deficient BM LSK cells in the microarray analysis.](gr3){#fig3}

![HP1 Depletion Compromises the Proliferation of HSCs\
(A) Western blot analysis of Lin^−^c-Kit^+^ fetal liver cells from *Tie2-Cre* and *Tie2-Cre;Tif1b*^fl/fl^ embryos. Levels of HP1 proteins were normalized to the amount of β-tubulin. The relative levels of HP1 proteins are indicated in the right panel. The data are shown as mean ± SEM (n = 3).\
(B) Immunostaining of HP1α and H3K9me3 in LSK cells from *Tie2-Cre* and *Tie2-Cre;Tif1b*^fl/fl^ fetal livers at E13.5. Cells were counterstained with DAPI. Representative three individual cell images are depicted. Numbers of chromocenters per cell are shown in the bottom panel. In total, 100 cells were counted for the scoring of the chromocenters.\
(C) Growth of CD34^−^KSL HSCs upon depletion of *Hp1* genes in vitro. HSCs were transduced with lentiviruses generating shRNAs against *Luciferase* (*Luc*), *Hp1a*, *Hp1b*, and *Hp1g* and then allowed to proliferate in the presence of 100 ng/ml of SCF and TPO for 14 days. The transduction efficiency was around 75% in most experiments as judged from the GFP expression. The data are shown as mean ± SEM for triplicate cultures.\
(D) Analysis of CD34^−^KSL HSC cultures depleted of *Hp1* genes in (C) at day 14. The proportion of LSK cells in GFP^+^ cells is shown. The data are shown as mean ± SEM (n = 3).](gr4){#fig4}
